Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.401 EUR | +1.27% | -0.69% | -45.88% |
Business Summary
- products derived from plasma (77.3%): products for use by the pharmaceutical and biotechnology industries;
- diagnostic machines and reagents (14.9%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers;
- hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies;
- other (5.4%): primarily intermediate biological products and subcontracted manufacturing services.
Net sales are distributed geographically as follows: Spain (5.3%), European Union (11.7%), the United States and Canada (63.6%) and other (19.4%).
Number of employees: 23,744
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharma
84.3
%
| 5,005 | 82.5 % | 5,558 | 84.3 % | +11.05% |
Diagnosis
10.2
%
| 671 | 11.1 % | 670 | 10.2 % | -0.15% |
Others
3.1
%
| 250 | 4.1 % | 203 | 3.1 % | -18.67% |
Bio Supplies
2.4
%
| 146 | 2.4 % | 160 | 2.4 % | +9.50% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States and Canada
59.1
%
| 3,856 | 63.6 % | 3,899 | 59.1 % | +1.12% |
Rest of World
21.8
%
| 1,176 | 19.4 % | 1,437 | 21.8 % | +22.19% |
Rest of European Union
13.5
%
| 712 | 11.7 % | 893 | 13.5 % | +25.50% |
Spain
5.5
%
| 321 | 5.3 % | 363 | 5.5 % | +13.18% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 65 | 06-04-04 | |
Director of Finance/CFO | 67 | 06-12-31 | |
Albert Coma-Cros
CTO | Chief Tech/Sci/R&D Officer | - | 03-12-31 |
55 | - | ||
Director/Board Member | 48 | 16-05-29 | |
Director/Board Member | 61 | 01-07-26 | |
Director/Board Member | 68 | 00-04-12 | |
Investor Relations Contact | 61 | 95-12-31 | |
Comptroller/Controller/Auditor | 45 | 15-12-31 | |
Human Resources Officer | 58 | 21-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 65 | 06-04-04 | |
Director/Board Member | 68 | 00-04-12 | |
Director/Board Member | 61 | 01-07-26 | |
Director/Board Member | 59 | 15-05-28 | |
Director/Board Member | 56 | 15-05-28 | |
James Costos
BRD | Director/Board Member | 61 | 20-10-08 |
Director/Board Member | 48 | 16-05-29 | |
Nacho Abia
BRD | Director/Board Member | 55 | Feb. 05 |
Director/Board Member | 59 | 19-05-23 | |
Director/Board Member | 47 | 22-06-09 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 261,425,110 | 256,479,163 ( 98.11 %) | 4,518,199 ( 1.728 %) | 94.98 % |
Stock B | 1 | 426,129,798 | 396,559,176 ( 93.06 %) | 3,944,430 ( 0.9256 %) |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
437,069,656 | 6.49% | 437,480,501 $ |
Company contact information
Grifols SA
Avinguda de la Generalitat, 152-158 Parc de Negocis Can Sant Joan
08174, Barcelona
+34 935 712 200
http://www.grifols.comGroup companies
Name | Category and Sector |
---|---|
Gri-Cel SA
Gri-Cel SA Financial ConglomeratesFinance Part of Grifols SA, Gri-Cel SA provides investment services. The private company is based in Barcelona, Spain. The CEO of the Spanish company is Dirk Büscher. |
Financial Conglomerates
|
Grifols India Healthcare Pvt Ltd.
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.91% | 5.44B | |
+0.44% | 90.27B | |
+10.00% | 44.05B | |
-16.40% | 31.45B | |
+44.49% | 23.35B | |
-8.10% | 16.72B | |
-25.64% | 15.09B | |
-9.03% | 12.82B | |
-9.37% | 11.95B | |
+98.58% | 7.67B |
- Stock
- Equities
- Stock Grifols, S.A. - BME
- Company Grifols, S.A.